Ligand Pharmaceuticals to acquire Pfenex in potential $516m deal
Ligand Pharmaceuticals has agreed to acquire Pfenex in an all-share transaction, priced at $12 per share, totalling an equity value of $438m in cash, on a fully diluted
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XLigand Pharmaceuticals has agreed to acquire Pfenex in an all-share transaction, priced at $12 per share, totalling an equity value of $438m in cash, on a fully diluted
Genentech, a subsidiary of the Roche Group, has received the US Food and Drug Administration (FDA) approval for Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) in adult
Pfizer has reached a multi-year agreement with Gilead Sciences to produce and supply the latter’s potential antiviral remdesivir for the treatment of Covid-19. Under the terms of the
Novartis has received the European Commission (EC) approval for Xolair (omalizumab) as an add-on therapy with intranasal corticosteroids (INC) to treat a type of severe chronic rhinosinusitis. The
US-based vaccine development firm Novavax has signed a license agreement with Serum Institute of India (SIIPL) for the development and commercialisation of its potential Covid‑19 vaccine candidate NVX‑CoV2373.
GlaxoSmithKline (GSK) has received the US Food and Drug Administration (FDA) approval for BLENREP (belantamab mafodotin-blmf) to treat a type of multiple myeloma. The FDA approval indicated BLENREP
Johnson & Johnson has agreed with the US government to domestically manufacture and deliver 100 million doses of potential Covid-19 vaccine Ad26.COV2.S, developed by its subsidiary Janssen. The
The UK government has agreed with Valneva, a French biotech firm focused on vaccines, to jointly invest in the expansion of the latter’s manufacturing facility in Scotland to
Novartis has unveiled positive results from the Phase 2 ELARA trial, which evaluated Kymriah (tisagenlecleucel) to treat patients with relapsed or refractory (r/r) follicular lymphoma (FL). The interim
Johnson & Johnson’s pharmaceutical business Janssen has secured the US Food and Drug Administration (FDA) approval for Spravato (esketamine) CIII nasal spray, to treat depression symptoms in major